Heart Failure

The 2 organizations released a joint statement on challenging the common view of HF as an inevitability and prioritizing preventive measures.

Over 11,000 bottles have been voluntarily recalled in response to a consumer complaint of a foreign substance inside a tablet, later identified as aluminum.

July delivered 9 impactful advancements across the gamut of disciplines in cardiology.

Panelists discuss differentiators between nsMRA and steroidal MRAs in the context of heart failure.

Panelists offer perspective on the role of finerenone in combination therapy approaches in patients with HFmrEF/HFpEF.

Finerenone's FDA approval marks a transformative step in heart failure treatment, offering early benefits and broad applicability.

Finerenone's FDA approval marks a breakthrough in heart failure treatment, significantly reducing cardiovascular events and hospitalizations for patients.

Combination therapy results in an overall reduction in 1-year mortality and hospitalizations compared to patients receiving SGLT2 inhibitors alone.

A recent study has suggested the efficacy of a common type 2 diabetes treatment in improving cardiac structure and metabolic control.

Fudim discusses his experiences in prescribing GLP-1 receptor agonists, as well as his opinions regarding remote patient monitoring.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.

This study highlights the rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use for heart failure within US ambulatory cardiovascular care settings.

The prespecified analysis of FINEARTS-HF found finerenone’s impact on HF events, cardiovascular death, and symptoms was not impacted by frailty.

According to recent research, more patients surviving heart diseases correlates directly to higher mortality rates for ischemic and chronic heart conditions.

Our June 2025 recap highlights significant advancements in cardiology, including new drug approvals and pivotal trial results.

Findings highlight an increased risk of MASLD, heart failure, type 2 diabetes, and other cardiometabolic diseases following cycles of weight loss and regain.

With so many new medications ostensibly filling the niche typically occupied by ACE/ARBs, are the medications practically useful in a changed treatment landscape?

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.

Most modern GDMT components were prescribed to less than half of all patients included in the EMPACE study, indicating the need for strategies to enhance clinical adoption.

Khan’s presentation indicates that combination screening is the optimal method of identifying heart failure risk while minimizing the percentage of cases missed.

The ACHIEVE trial found use of spironolcatone was not associated with a statistically significant reduction in cardiovascular death or hospitalization for HF.

Investigators compared the efficacy of tirzepatide and liraglutide in lowering rates of all-cause mortality in patients with obesity and sleep apnea.

Compared to age-matched controls, women with premature menopause had greater risks of all-cause mortality and multiple cardiovascular complications.